

Curriculum Vitae

Name in Full	Edward Kim, MD
Country	USA
Affiliation	Mount Sinai Hospital
Email	Edward.Kim@mountsinai.org

Educational Background

GRADUATE MEDICAL EDUCATION

Fellow , Vascular and Interventional Radiology	Mount Sinai Medical Center, New York, NY
Resident , Diagnostic Radiology	Nassau University Medical Center, East Meadow, NY
Intern , Transitional Year	Atlantic Health Systems, Morristown, NJ

MEDICAL EDUCATION

Rutgers Medical School - Newark, NJ
Doctorate of Medicine

UNDERGRADUATE AND GRADUATE EDUCATION

Georgetown University, Washington, DC

- Masters of Science in Physiology

Rutgers College – Rutgers University, New Brunswick, NJ

- Bachelor of Arts in Biology and Psychology

Professional Career

Director, Interventional Oncology
Division of Vascular and Interventional Radiology
Mount Sinai Health System, New York, NY

Professor of Radiology and Surgery
The Icahn School of Medicine at Mount Sinai, New York, NY

1. **Kim E**, Sher A, Abboud G, Schwartz M, Facciuto M, Tabrizian P, Knesaurek K, Fischman A, Patel R, Nowakowski F, Llovet J, Taouli B, and Lookstein R. RAdiation SEgmentectomy for curative intent of unresectable HCC (RASER): A prospective, single arm study. *The Lancet Gastroenterology & Hepatology*. March 2022.
1. Salem R, Johnson G, **Kim E**, Riaz A, Bishay V, Boucher E, Fowers K, Lewandowski R, and Padia S. Yttrium 90 Radioembolization for the treatment of solitary, unresectable hepatocellular carcinoma: The LEGACY Study. *HEPATOLOGY*. 2021 March.
2. *Marinelli B, Marron T, **Kim E**. Safety of Locoregional Treatment During Immunotherapy With Nivolumab For Hepatocellular Carcinoma: A Retrospective Study of Forty-one Interventions in Twenty-nine Patients. *JVIR* 2020.
3. *O'Connor, Pasik S, van der Bom M, Bishay V, Radaelli A, **Kim E**. Feasibility of yttrium-90 radioembolization dose calculation utilizing intra-procedural open trajectory cone beam CT. *CVIR*. 2020 Feb; 43(2):295-301.
4. *Hardy-Abeloos C, Lazarev S, Ru M, **Kim E**, Fischman A, Moshier E, Rosenzweig K, Buckstein M. Safety and Efficacy of liver stereotactic body radiation therapy for hepatocellular carcinoma following segmental transarterial radioembolization. *Int J Radiat Oncol Biol Phys*. 2019 Sep 16.
5. *Labгаа I, Tabrizian P, Titano JJ, **Kim E**, Thung SN, Florman S, Schwartz M, Melloul E. Feasibility and safety of liver transplantation or resection after transarterial radioembolization with Yttrium-90 for unresectable hepatocellular carcinoma. *HPB (Oxford)*. 2019 Apr 17.
6. *McGee HM, King MJ, Ozbek U, Olson A, **Kim E**, Fischman AM, Schwartz M, Rosenzweig K, Buckstein M. Dual Modality Radiation With External Beam Radiation Therapy and Transarterial Radioembolization for Hepatocellular Carcinoma with Gross Vascular Invasion. *Am J Clin Oncol*. 2019 Apr; 42(4):367-374.
7. *Biederman DM, Titano JJ, Korff R, Lookstein R, Fischman AM, Patel RS, Nowakowski FS, **Kim E**. Radiation Segmentectomy vs. Selective Chemoembolization in the Treatment of Early-Stage Hepatocellular Carcinoma. *JVIR*. 2018 Jan 29; 1: 30-37.
8. *Biederman DM, Posham R, Durrani RJ, Titano JJ, Patel RS, Tabori NE, Nowakowski FS, Fischman AM, Lookstein RA, **Kim E**. Outcomes of radioembolization for unresectable hepatocellular carcinoma in patients with marginal functional hepatic reserve. *Clin Imaging*. 2017 Jul 20;47:34-40.
9. *Biederman DM, Dayan E, Tabori NE, Schwartz M, Facciuto ME, Gunasekaran G, Florman S, Fischman AM, Patel RS, Nowakowski FS, **Kim E**. Radiation Segmentectomy vs. Transarterial Chemoembolization Combined with Microwave Ablation for Unresectable Solitary Hepatocellular Carcinoma ≤ 3 cm: A Propensity Score Matching Study. *Radiology*. 2017 Jun; 283(3):895-905.
10. *Swinburne, N. C., Biederman, D. M., Besa, C., Tabori, N. E., Fischman, A. M., Patel, R. S., Nowakowski, F. S., Gunasekaran, G., Schwartz, M. E., Lookstein, R. A., & **Kim, E.** (2017). Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma: Review of Safety, Response

Beyond the COVID-19 Pandemic, Enjoy the Collaboration and Innovation in GI Intervention!
Evaluation Criteria in Solid Tumors 1.1 Imaging Response and Survival. Cancer Biother

Radiopharm, 32(5), 161-168.

11. *Biederman DM, Titano JJ, Tabori NE, Pierobon ES, Alshebeeb K, Schwartz M, Facciuto ME, Gunasekaran G, Florman S, Fischman AM, Patel RS, Nowakowski FS, **Kim E**. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres. *J Vasc Interv Radiol*. 2016 Apr 6. pii: S1051-0443(16)00201-3.
12. *Biederman D, Titano J, Lee K, Pierobon E, Schwartz M, Facciuto M, Gunasekaran G, Florman S, Fischman A, Patel R, Tabori N, Nowakowski F, and **Kim E**. Yttrium-90 glass-based microsphere radioembolization in the treatment of hepatocellular carcinoma secondary to the hepatitis B virus: safety, efficacy, and survival. *J Vasc Interv Radiol*. 2015 Nov; 26(11):1630-8.
13. **Kim E**, Ward T, Patel RS, Fischman AM, Nowakowski FS, Lookstein RA. (2014). CT-Guided Liver Biopsy with Electromagnetic Tracking Assistance: Results from a Single-Center, Prospective Randomized-Control Trial. *American Journal of Radiology*, December 2014.
14. Vouche M, Habib A, Ward T, **Kim E**, Kulik L, Ganger D, Mulcahy M, Baker T, Abecassis M, Sato KT, Caicedo JC, Fryer J, Hickey R, Hohlastos E, Lewandowski R, Salem R. (2014). Unresectable Solitary HCC not Amenable to RFA: Multicenter Radiology-Pathology Correlation and Survival of Radiation Segmentectomy. *Hepatology*. 2014 Apr 19.

Research Field

My clinical research has focused on the field of minimally invasive procedures for treatment of cancer. Through interdisciplinary collaboration with the division of liver transplantation, medical oncology, radiation oncology and surgical oncology, numerous publications have been generated related to radiofrequency ablation, microwave ablation, transarterial chemoembolization, radioembolization and electromagnetic tracking for image guidance for the treatment of primary and metastatic liver cancer. I have participated and published in multi-center trials that have studied the use of novel devices for the treatment of liver cancer.